F10 and triple-A syndrome: To test whether AAA is dependent on coagulation factor activity in this model, we administered the direct FXa inhibitor rivaroxaban via chow to male ApoE−/− mice during Ang II administration and found significantly less AAA developed (SI Appendix, Fig. S6B).